Literature review summarizes effects of GH replacement therapy on quality of life in GHD patients, highlighting ongoing challenges.
Childhood and adult patients with growth hormone deficiency (GHD) experience a variety of physical, metabolic, and psychological problems that collectively lower quality of life (QoL). Recombinant human growth hormone (rhGH) has transformed treatment by improving growth body composition, energy levels, and mental health. Nevertheless, further research is needed to determine the full scope of these QoL gains. This review of the literature summarizes current research on how growth hormone (GH) replacement therapy affects GHD patients' quality of life based on longitudinal studies, metaanalyses, and clinical trials. Although GH therapy has demonstrated advantages in several QoL areas, issues still exist, such as patient response variability, the sustainability of long-term treatment, and possible adverse effects. The effectiveness of GH therapy, the methods used to evaluate QoL outcomes, and the necessity of individualized treatment approaches are all clarified by this review's analysis of the most recent data. Future research should validate current QoL tools, assess the long-term safety of GH therapy, and develop improved methods for monitoring treatment outcomes to enhance personalized care and overall well-being in GHD patients.
No takes yet. Share an insight, caveat, or question.
Almutairi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: